What's New

Last Posted: Jun 13, 2024

• Implementation of and Systems-Level Barriers to Guideline-Driven Germline Genetic Evaluation in the Care of Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia.
  Lauren G Banaszak et al. JCO Precis Oncol 2024 8e2300518
• Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia
  
• Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia.
  Andrew Seto et al. Cancers (Basel) 2024 16(9)
• Advancing hospital-based health technology assessment: evaluating genomic panel contracting strategies for blood tumors through a multimethodology.
  Susana Afonso et al. Int J Technol Assess Health Care 2023 39(1) e76
• The Clinical Utility of FLT3 Mutation Testing in Acute Leukemia: A Canadian Consensus.
  Julie Bergeron et al. Curr Oncol 2023 30(12) 10410-10436
• Older Patients With AML Less Likely to Receive Genomic Testing, Study Finds
  P Steinzor, AJMC, August 29, 2023
• Management of Down Syndrome-Associated Leukemias: A Review.
  Anupam Verma et al. JAMA Oncol 2023
• Telomere Length and Clonal Hematopoiesis.
  George Vassiliou et al. N Engl J Med 2023 5 (26) 2481-2484
• Molecular Heterogeneity of Pediatric AML with Atypical Promyelocytes Accumulation in Children-A Single Center Experience.
  Aleksandra Borkovskaia et al. Genes 2023 14(3)
• A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.
  Qiujin Shen et al. Cancer research communications 2023 2(4) 258-276
• The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency.
  Marta Santiago et al. Cancers 2023 15(5)
• Comprehensive analysis of PTPN family expression and prognosis in acute myeloid leukemia.
  Yong Liu et al. Frontiers in genetics 2023 131087938
• Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry.
  Sargas Claudia et al. Cancers 2023 15(2)
• Acute myeloid leukemia: challenges for diagnosis and treatment in Latin America.
  Gómez-De León Andrés et al. Hematology (Amsterdam, Netherlands) 2023 28(1) 2158015
• Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease.
  Fitzhugh Courtney D et al. Hematology. American Society of Hematology. Education Program 2022 2022(1) 266-271
• Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.
  Ganzel Chezi et al. Leukemia research 2022 123106971
• Unified classification and risk-stratification in Acute Myeloid Leukemia.
  Tazi Yanis et al. Nature communications 2022 8 (1) 4622
• Screening a Targeted Panel of Genes by Next-Generation Sequencing Improves Risk Stratification in Real World Patients with Acute Myeloid Leukemia.
  Matos Sónia et al. Cancers 2022 14(13)
• Pan-cancer analysis reveals distinct clinical, genomic, and immunological features of the LILRB immune checkpoint family in acute myeloid leukemia.
  Xu Zi-Jun et al. Molecular therapy oncolytics 2022 2688-104
• How Genetics Can Drive Initial Therapy Choices for Older Patients with Acute Myeloid Leukemia.
  Moore Jozal W et al. Current treatment options in oncology 2022
• Molecular genetic and clinical characterization of acute myeloid leukemia with trisomy 8 as the sole chromosome abnormality.
  Liu Jie et al. Hematology (Amsterdam, Netherlands) 2022 27(1) 565-574
• A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear.
  Wang Meifang et al. Frontiers in oncology 2022 12844978
• Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions.
  Qin Wei et al. Turkish journal of haematology : official journal of Turkish Society of Haematology 2022
• WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients.
  Koczkodaj Dorota et al. Journal of clinical medicine 2022 11(7)
• A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients.
  Yang Min et al. Frontiers in oncology 2022 11783114
• A Machine Learning Approach to the Classification of Acute Leukemias and Distinction From Nonneoplastic Cytopenias Using Flow Cytometry Data.
  Monaghan Sara A et al. American journal of clinical pathology 2021
• Incorporating genetic counseling into the evaluation of pediatric bone marrow failure.
  Schneider Kami Wolfe et al. Journal of genetic counseling 2021
• Adult Acute Myeloid Leukemia with the KMT2A-Mixed Lineage Leukemia T10 Fusion: An Analysis of 10 Cases Showed Common Features and Frequent Mutations in the RAS Signaling Pathway.
  Cai Xiaohui et al. Acta haematologica 2021 1-7
• Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia.
  Wang Youjin et al. Scientific reports 2021 11(1) 15004
• DNA methylation analysis improves the prognostication of acute myeloid leukemia.
  Samimi Hanie et al. EJHaem 2021 2(2) 211-218
• An overview of genetic predisposition to familial hematological malignancies.
  Hamadou Walid Sabri et al. Bulletin du cancer 2021
• Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.
  Barnell Erica K et al. JCO precision oncology 2021 5
• Alternative splicing redefines landscape of commonly mutated genes in acute myeloid leukemia.
  Rivera Osvaldo D et al. Proceedings of the National Academy of Sciences of the United States of America 2021 118(15)
• Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.
  Duncavage Eric J et al. The New England journal of medicine 2021 384(10) 924-935
• [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
  Zhang Li-Juan et al. Zhongguo shi yan xue ye xue za zhi 2020 Dec 28(6) 1985-1990
• Informed consent for genetic testing in hematology.
  Marron Jonathan M et al. Hematology. American Society of Hematology. Education Program 2020 2020(1) 213-218
• Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
  A Burd et al, Nature Medicine, October 26, 2020
• GATA2 Related Conditions and Predisposition to Pediatric Myelodysplastic Syndromes.
  Bruzzese Antonella et al. Cancers 2020 Oct 12(10)
• Acute myeloid leukemia and artificial intelligence, algorithms and new scores.
  Radakovich Nathan et al. Best practice & research. Clinical haematology 2020 Sep 33(3) 101192
• Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia.
  Ma Bei-Bei et al. American journal of translational research 2020 12(9) 4840-4852
• Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ KMT2A .
  Bill Marius et al. Proceedings of the National Academy of Sciences of the United States of America 2020 Oct
• DNA Repair Expression Profiling to Identify High-Risk Cytogenetically Normal Acute Myeloid Leukemia and Define New Therapeutic Targets.
  Gabellier Ludovic et al. Cancers 2020 Oct 12(10)
• Aberrant Chloride Intracellular Channel 4 Expression Is Associated With Adverse Outcome in Cytogenetically Normal Acute Myeloid Leukemia.
  Huang Sai et al. Frontiers in oncology 2020 101648
• Cyclosporine Broadens the Therapeutic Potential of Lenalidomide in Myeloid Malignancies.
  Dou Aixia et al. Journal of cellular immunology 2020 2(5) 237-244
• The Evolving Landscape of Myelodysplastic Syndrome Prognostication.
  Shreve Jacob et al. Clinical hematology international 2020 Jun 2(2) 43-48
• Identifying a novel 5-gene signature predicting clinical outcomes in acute myeloid leukemia.
  Sha K et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2020 Aug
• Prognostic role of ACTL10 in Cytogenetic Normal Acute Myeloid Leukemia.
  Lai Rui et al. Journal of Cancer 2020 11(17) 5150-5161
• Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine-based chemotherapy.
  Ni Jing et al. International journal of laboratory hematology 2020 Jul
• Monitoring and treatment of MDS in genetically susceptible persons.
  Davies Stella M et al. Hematology. American Society of Hematology. Education Program 2019 2019(1) 105-109
• Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
  Yun Seongseok et al. Leukemia research 2019 84106194

More